Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.44 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.53 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SCD | O00767 | 1/20 | 0.46 |
| ▸ | ACP1 | P24666 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2423252 | 0.92 | CSNK1D (0.60) | CSNK1DRAB9ANPC1SMN1; SMN2TP53 | |
| Fumaric Acid SCHEMBL2380684 | 0.90 | CSNK1D (0.67) | CSNK1DRAB9ANPC1SMN1; SMN2TP53 | |
| Fumaric Acid SCHEMBL2380245 | 0.90 | CSNK1D (0.45) | CSNK1DRAB9ANPC1KDM4EMAPT | |
| Fumaric Acid SCHEMBL2380818 | 0.87 | NPC1 (0.46) | CSNK1DRAB9ANPC1KDM4EMAPT | |
| SCHEMBL2421008 | 0.82 | CSNK1D (0.71) | CSNK1DRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL2420475 | 0.81 | CSNK1D (0.46) | CSNK1DRAB9ANPC1KDM4EMAPT | |
| SCHEMBL2450558 | 0.80 | NPC1 (0.56) | CSNK1DRAB9ANPC1SMN1; SMN2DYRK1A | |
| Fumaric Acid SCHEMBL2381292 | 0.78 | CSNK1D (0.69) | CSNK1DRAB9ANPC1SMN1; SMN2TP53 | |
| SCHEMBL2426475 | 0.78 | NPC1 (0.47) | CSNK1DRAB9ANPC1KDM4EMAPT | |
| SCHEMBL17287832 | 0.74 | CSNK1D (1.00) | CSNK1DRAB9ANPC1SMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037016-A1 | GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND (DE) | 2017-02-09 | — | — | US | disclosed |
| US-9475782-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-10-25 | — | — | US | disclosed |
| US-20130324537-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBOTT LABORATORIES (US) | 2013-12-05 | — | — | US | disclosed |
| US-8481576-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | ABBOTT GMBH & CO. KG (DE) | 2013-07-09 | — | — | US | disclosed |
| US-8431604-B2 | Guanidine compounds, and use thereof as binding partners for 5-HT5 receptors | ABBOTT GMBH & CO. KG (DE) | 2013-04-30 | — | — | US | disclosed |
| US-20110237589-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20070299074-A1 | Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2007-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130324537-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, TAAR5 | KMT2A 4155/4885CSNK1D 4090/4885RAB9A 1420/4885 |
| US-20170037016-A1 | GUANIDINE COMPOUNDS AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, GRK5 | KMT2A 4154/4885CSNK1D 3915/4885RAB9A 1428/4885 |
| US-20070299074-A1 | Guanidine Compounds, and Use Thereof as Binding partners for 5-Ht5 Receptors | HTR5A, GRM5, TAAR5 | KMT2A 4155/4885CSNK1D 4090/4885RAB9A 1420/4885 |
| US-20110237589-A1 | GUANIDINE COMPOUNDS, AND USE THEREOF AS BINDING PARTNERS FOR 5-HT5 RECEPTORS | HTR5A, GRM5, TAAR5 | KMT2A 4155/4885CSNK1D 4090/4885RAB9A 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.